Boston Scientific (BSX) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $72.85B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Michael F. Mahoney |
| IPO Date | 1992-05-19 | CAGR | 14.05% |
| Employees | 59,000 | Website | www.bostonscientific.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $69.19B | P/E | 15.81 | Forward P/E | 14.27 | PEG | 1.35 |
| P/S | 20.15 | P/B | 16.25 | P/CF | 96.85 | P/FCF | 122.85 |
| Sales | $21.00B | Sales 1Y | 13.53% | Sales 3Y | 56.69% | Sales 5Y | 87.54% |
| EPS | $3.1 | EPS 1Y | 46.73% | EPS 3Y | 313.51% | EPS 5Y | 653.91% |
| Sales QoQ | 4.61% | EPS QoQ | -32.22% | Sales QoQ Avg | 1.87% | EPS QoQ Avg | 13.03% |
| Gross Margin | 71.16% | Operating Margin | 21.6% | Profit Margin | 17.48% | ROCE | 11.4% |
| ROA | 8% | ROE | 15% | Altman Z Score | 3.55 | Piotroski Score | 6 |
| Current Ratio | 1.9 | Quick Ratio | 1.22 | Cash Ratio | 0.33 | Op. CF Ratio | 0.08 |
| Debt/Equity | 0.43 | Debt/Assets | 0.25 | Lt Debt/Equity | 0.42 | Lt Debt/Cap. | 0.3 |
| Intrst Cov. | -503.89 | Inventory Turnover | 1.94 | Asset Turnover | 0.47 | Receivables Turnover | 6.94 |
| Enterprise Value | $69.19B | P/E Ratio | 15.81 |
| Forward P/E | 14.27 | PEG Ratio | 1.35 |
| P/S Ratio | 20.15 | P/B Ratio | 16.25 |
| P/CF Ratio | 96.85 | P/FCF Ratio | 122.85 |
| EPS | $3.1 | EPS Growth 1Y | 46.73% |
| EPS Growth 3Y | 313.51% | EPS Growth 5Y | 653.91% |
| Revenue Growth 1Y | 13.53% | Gross Margin | 0.71% |
| Operating Margin | 0.22% | Profit Margin | 0.17% |
| ROE | 0.15% | ROA | 0.08% |
| ROCE | 0.11% | Current Ratio | 1.9 |
| Quick Ratio | 1.22 | Cash Ratio | 0.33 |
| Debt/Equity | 0.43 | Interest Coverage | -503.89 |
| Altman Z Score | 3.55 | Piotroski Score | 6 |
Boston Scientific (BSX) valuation & financials
Boston Scientific (BSX) has a market capitalization of $72.85B and trades at a price-to-earnings ratio of 15.8. It operates in the Healthcare sector (Medical - Devices).
Boston Scientific's revenue grew +13.5% over the last year.
Boston Scientific's next earnings report is scheduled for October 28, 2026 before market open; analysts estimate EPS of $0.80. Check the earnings calendar to see all companies reporting this week.
Boston Scientific (BSX) — frequently asked questions
When does Boston Scientific (BSX) report earnings next?
Boston Scientific is expected to report earnings on October 28, 2026 before market open. Analysts estimate EPS of $0.80.
What is Boston Scientific's market cap?
Boston Scientific (BSX) has a market capitalization of $72.85B.
What is BSX's P/E ratio?
Boston Scientific trades at a price-to-earnings ratio of 15.8, with trailing twelve-month EPS of $3.10.
How fast is Boston Scientific growing?
Boston Scientific's revenue grew +13.5% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)